TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33823163

Group type: EXPERIMENTAL
Intervention: Anodal tDCS, applied to the primary occipital cortex (Oz) for 20 min at 1.5 mA intensity
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS, applied to the primary occipital cortex (Oz) for 20 min at 1.5 mA intensity
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham stimulation, applied to the middle of the head (Cz) for 20 min
Number of subjects: 50
Study: 34617561

Group type: EXPERIMENTAL
Intervention: FODMAPs (50 g/d)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Gluten (17.3 g/d)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 34391566

Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir plus rilpivirine
Number of subjects: 0
Study: 34518276

Group type: EXPERIMENTAL
Intervention: PRO-symptom monitoring using a web application with active and reactive alert approaches.
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: PRO-symptom monitoring using a web application.
Number of subjects: 584

Group type: COMPARATOR
Intervention: Control group (no PRO-symptom monitoring).
Number of subjects: 584
Study: 32215653

Group type: EXPERIMENTAL
Intervention: Fat grafting
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (intact side of abdomen)
Number of subjects: 10
Study: 35576072

Group type: EXPERIMENTAL
Intervention: SMR–Beta1 neurofeedback training (12–18 Hz) for 10 sessions (3 days a week)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (without any NFB training)
Number of subjects: 24
Study: 34616618

Group type: EXPERIMENTAL
Intervention: 3 g of copra meal hydrolysate (CMH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 g of copra meal hydrolysate (CMH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 34196787

Group type: EXPERIMENTAL
Intervention: Acute Resistance Exercise (RE)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acute Aerobic Exercise (AE)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acute Aerobic Exercise (AE) and Acute Resistance Exercise (RE)
Number of subjects: 6
Study: 32591170

Group type: EXPERIMENTAL
Intervention: neuroplasticity based computerized cognitive remediation (nCCR) for 30 hours over 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: neuroplasticity based computerized cognitive remediation (nCCR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: active control condition
Number of subjects: 0
Study: 34172486

Group type: EXPERIMENTAL
Intervention: Classroom sensitisation session delivered by a lay counsellor (IC)
Number of subjects: 835

Group type: COMPARATOR
Intervention: Whole-school sensitisation (teacher-meetings and whole-school activities) (CC)
Number of subjects: 835
Study: 35925755

Group type: EXPERIMENTAL
Intervention: Ada app-based diagnostic tool
Number of subjects: 450

Group type: COMPARATOR
Intervention: Classic doctor-patient interaction
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Combined diagnostic accuracy of Ada and ER physician
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Early diagnosis and rapid treatment allocation
Number of subjects: 450
Study: 34197486

Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention (12-week progressive multi-component programme)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention
Number of subjects: 35
Study: 33463655

Group type: EXPERIMENTAL
Intervention: Centesys model
Number of subjects: 20

Group type: COMPARATOR
Intervention: agar-based model
Number of subjects: 20
Study: 35413774

Group type: EXPERIMENTAL
Intervention: Red-fleshed apple (RFA)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: ACN-rich infusion from aronia fruit (ARO)
Number of subjects: 121
Study: 33464924

Group type: EXPERIMENTAL
Intervention: Combined double‐bundle ACLR and ALSA (ALSA group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isolated double‐bundle ACLR (ACLR group)
Number of subjects: 16
Study: 35941264

Group type: EXPERIMENTAL
Intervention: FGF‐2‐CP composite layer‐coated screws subjected to gamma‐ray sterilization at 25 kGy (GS group)
Number of subjects: 2

Group type: COMPARATOR
Intervention: FGF‐2‐CP composite layer‐coated screws subjected to aseptic storage (AS group)
Number of subjects: 2
Study: 33228756

Group type: EXPERIMENTAL
Intervention: RFA/PVA and EBRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: EBRT alone
Number of subjects: 0
Study: 33829274

Group type: EXPERIMENTAL
Intervention: self-hypnosis/self-care
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: music/self-care
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: self-care
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: psychoeducation/cognitive behavioural therapy
Number of subjects: 575

Group type: COMPARATOR
Intervention: randomized treatment
Number of subjects: 575

Group type: COMPARATOR
Intervention: waiting more than 4 months before starting treatment
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: intermediate or high educational level
Number of subjects: 575
Study: 34782961

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 32247522

Group type: EXPERIMENTAL
Intervention: Perineural administration of 40‐mg ketamine plus 0.375% ropivacaine in 40‐mL volume (Group RNK)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 40 mL of 0.375% ropivacaine plus IV ketamine 40 mg (Group RIK)
Number of subjects: 76

Group type: COMPARATOR
Intervention: 40 mL of 0.375% ropivacaine (Group R)
Number of subjects: 76
Study: 36173235

Group type: EXPERIMENTAL
Intervention: BP with fast-acting insulin aspart (BP-F), N=114
Number of subjects: 275

Group type: COMPARATOR
Intervention: BP with standard care insulin delivery (SC), N=54
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: BP with aspart or lispro (BP-A/L), N=107
Number of subjects: 275
Study: 33792623

Group type: EXPERIMENTAL
Intervention: Tislelizumab (200 mg, day 1) plus paclitaxel (175 mg/m2, day 1) and carboplatin (area under the concentration of 5, day 1)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Tislelizumab plus nab-paclitaxel (100 mg/m2, days 1, 8, and 15) and carboplatin
Number of subjects: 355

Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin
Number of subjects: 355
Study: 32075406

Group type: EXPERIMENTAL
Intervention: Eptinezumab 30 mg
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 888

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 888
Study: 34490801

Group type: EXPERIMENTAL
Intervention: Breast cancer patients with perception about Vitamin D deficiency
Number of subjects: 402

Group type: COMPARATOR
Intervention: Control group (randomly selected females) with perception about Vitamin D deficiency
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Women aged 41 to 50 years
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Urban women
Number of subjects: 402
Study: 34175638

Group type: EXPERIMENTAL
Intervention: SAPB with 30 ml of 0.5% ropivacaine
Number of subjects: 198

Group type: COMPARATOR
Intervention: 0.9% normal saline (Control group)
Number of subjects: 198
Study: 36436481

Group type: EXPERIMENTAL
Intervention: Zafirlukast 10 mg BD for 10 days plus standard care
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo plus standard care
Number of subjects: 40
Study: 33221027

Group type: COMPARATOR
Intervention: Silexan 80 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Silexan 80 mg/d (multiple dosing for 7 days)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Silexan 160 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Silexan 320 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 75
Study: 32245512

Group type: EXPERIMENTAL
Intervention: Music listening for a minimum of 30 minutes at bedtime for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 0
Study: 36163686

Group type: EXPERIMENTAL
Intervention: active intermittent theta burst stimulation (iTBS)
Number of subjects: 81

Group type: COMPARATOR
Intervention: sham intermittent theta burst stimulation (iTBS)
Number of subjects: 81
Study: 33980763

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 2723

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2723
Study: 32729843

Group type: EXPERIMENTAL
Intervention: Self-monitoring program
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Remote monitoring program
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 122
Study: 36445905

Group type: EXPERIMENTAL
Intervention: CPI monitor turned on (intervention arm)
Number of subjects: 525

Group type: COMPARATOR
Intervention: CPI monitor turned off (control arm)
Number of subjects: 525
Study: 35340950

Group type: EXPERIMENTAL
Intervention: King Vision videolaryngoscope
Number of subjects: 100

Group type: COMPARATOR
Intervention: CMAC D blade videolaryngoscope
Number of subjects: 100
Study: 36028073

Group type: EXPERIMENTAL
Intervention: HIIE-D (Two sessions of high-intensity interval exercise separated by 3 hours)
Number of subjects: 20
Study: 33591469

Group type: EXPERIMENTAL
Intervention: 4 mg intravenous ZOL every 3 weeks for 1 year (17 total doses)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 120
Study: 35359478

Group type: EXPERIMENTAL
Intervention: Bilateral nasociliary and maxillary nerve blocks with 12 mL of equal volumes of 0.5% bupivacaine and 2% lignocaine after induction of general anaesthesia
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Bilateral nasociliary and maxillary nerve blocks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 51
Study: 33217697

Group type: EXPERIMENTAL
Intervention: Loading rate of 8.3 kN/s at 0.5 Hz
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Loading rate of 4.2 kN/s at 0.5 Hz
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Loading rate of 8.3 kN/s at 1 Hz
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Loading rate of 4.2 kN/s at 1 Hz
Number of subjects: 32
Study: 36263451

Group type: EXPERIMENTAL
Intervention: Daily emollient plus standard skin‐care advice
Number of subjects: 1394

Group type: COMPARATOR
Intervention: Standard skin‐care advice alone
Number of subjects: 1394
Study: 33880760

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg orally alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rifampin 600 mg i.v. infusion
Number of subjects: 10
Study: 32290859

Group type: EXPERIMENTAL
Intervention: Goal-Focused Emotion-Regulation Therapy (GET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual Supportive Therapy (ISP)
Number of subjects: 0
Study: 33461308

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4456

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4456
Study: 32087762

Group type: EXPERIMENTAL
Intervention: Low-pressure group (7 mm Hg)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard-pressure group (12 mm Hg)
Number of subjects: 138
Study: 36107179

Group type: EXPERIMENTAL
Intervention: Standard therapy
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Standard therapy + homeopathic protocol
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Homeopathic protocol
Number of subjects: 154
Study: 34941168

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided quadratus lumborum block (QLB) with 20 mL of 0.25% ropivacaine on each side
Number of subjects: 62

Group type: COMPARATOR
Intervention: General anesthesia (control)
Number of subjects: 62
Study: 32111521

Group type: EXPERIMENTAL
Intervention: Brazil nut supplementation (one unit daily for 3 months)
Number of subjects: 32
Study: 34774185

Group type: EXPERIMENTAL
Intervention: IVIG (2 g/kg over 4 days)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9% equivalent volume over the same period)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 33256887

Group type: EXPERIMENTAL
Intervention: Blog written by a registered dietitian (RD)
Number of subjects: 26
Study: 33167114

Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTA)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (elective ICA examination)
Number of subjects: 102
Study: 33217092

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor (SGLT2i)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (TZD)
Number of subjects: 119
Study: 33686037

Group type: EXPERIMENTAL
Intervention: 2% lignocaine with 1:50,000 epinephrine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 120
Study: 36120142

Group type: EXPERIMENTAL
Intervention: Cultural and creative product design in sports events
Number of subjects: 620

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 620
Study: 33685306

Group type: EXPERIMENTAL
Intervention: Glucocorticoid (GC) injection
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 32641747

Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 1864

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1864
Study: 34216500

Group type: EXPERIMENTAL
Intervention: Mobile app for capturing supplemental health information during pregnancy
Number of subjects: 64
Study: 34429410

Group type: EXPERIMENTAL
Intervention: Genome sequencing (GS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (family histories of disease review only)
Number of subjects: 200
Study: 32969999

Group type: EXPERIMENTAL
Intervention: Jackknife position
Number of subjects: 10
Study: 34628232

Group type: EXPERIMENTAL
Intervention: Blind weighing
Number of subjects: 53

Group type: COMPARATOR
Intervention: Open weighing
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups (Blind and Open weighing)
Number of subjects: 53
Study: 34674574

Group type: EXPERIMENTAL
Intervention: Aerosolized tromethamine (THAM)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 32
Study: 32846806

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no NHF therapy)
Number of subjects: 0
Study: 35465804

Group type: EXPERIMENTAL
Intervention: Shared governance intervention
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 318
Study: 34872628

Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Literature control condition
Number of subjects: 244
Study: 36057390

Group type: EXPERIMENTAL
Intervention: Four-staged invitation procedure (pre-notification, invitation, and two reminders)
Number of subjects: 59041

Group type: EXPERIMENTAL
Intervention: Three-staged invitation procedure (invitation and two reminders)
Number of subjects: 59041

Group type: COMPARATOR
Intervention: Three-staged invitation procedure (pre-notification, invitation, and one reminder)
Number of subjects: 59041

Group type: EXPERIMENTAL
Intervention: Extra reminder
Number of subjects: 59041

Group type: EXPERIMENTAL
Intervention: Four-staged invitation procedure (specifically for age group 50-59 years)
Number of subjects: 59041
Study: 33849035

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 0
Study: 35137345

Group type: EXPERIMENTAL
Intervention: Choriomon® (10,000 IU)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ovitrelle® (250 µg; 6500 IU)
Number of subjects: 26
Study: 33333105

Group type: EXPERIMENTAL
Intervention: Caffeine intake ≥232 mg/day
Number of subjects: 121374

Group type: EXPERIMENTAL
Intervention: Caffeine intake >480 mg/day
Number of subjects: 121374

Group type: EXPERIMENTAL
Intervention: Caffeine intake ≥321 mg/day
Number of subjects: 121374

Group type: EXPERIMENTAL
Intervention: Caffeine intake (general)
Number of subjects: 121374

Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis
Number of subjects: 121374
Study: 34216838

Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR) - 5 hours sleep opportunity per night for 9 nights
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Weekend Recovery (WR) - 5 hours sleep opportunity per night for 4 nights followed by ad libitum weekend recovery sleep
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control - 9 hours sleep per night
Number of subjects: 20
Study: 34052092

Group type: EXPERIMENTAL
Intervention: Normal saline instillation (NSI)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure recruitment manoeuvre (RM)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No normal saline instillation (no NSI)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No recruitment manoeuvre (no RM)
Number of subjects: 58
Study: 35721180

Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate-Remifentanil (RT-RF)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Dexmedetomidine-Remifentanil (Dex-RF)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Remimazolam Tosilate-Remifentanil (RT-RF) vs Dexmedetomidine-Remifentanil (Dex-RF)
Number of subjects: 146
Study: 33006190

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35952357

Group type: EXPERIMENTAL
Intervention: ART adherence measured by hair tenofovir (TFV) levels post breastfeeding cessation
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Doubling of hair TFV concentration
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Viremia frequency
Number of subjects: 55
Study: 33687126

Group type: EXPERIMENTAL
Intervention: Duodenal eosinophilia at baseline (D1 eosinophilia)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Healthy controls (no duodenal eosinophilia)
Number of subjects: 213
Study: 34757919

Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 256

Group type: COMPARATOR
Intervention: PM20D1, C18:1‐Leu and C18:1‐Phe levels
Number of subjects: 256
Study: 35039263

Group type: EXPERIMENTAL
Intervention: Kangfuyan capsule combined with antibiotics (azithromycin + metronidazole)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Oral antibiotics (azithromycin + metronidazole) alone (control group)
Number of subjects: 83
Study: 32130164

Group type: EXPERIMENTAL
Intervention: Medication Ambient Display (MAD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no MAD)
Number of subjects: 16
Study: 36420938

Group type: EXPERIMENTAL
Intervention: OL-HDF using FxCordiax HDF 800™
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Elisio 21HX™
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Theranova 500®
Number of subjects: 14
Study: 34475873

Group type: EXPERIMENTAL
Intervention: Nasal Foralumab (100ug/day) given for 10 consecutive days with 6 mg dexamethasone given on days 1-3 (n=11)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nasal Foralumab alone (100ug/day) given for 10 consecutive days (n=12)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control, no Foralumab (n=16)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nasal Foralumab (100ug/day) and Foralumab/Dexa treated subjects
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Foralumab treatment
Number of subjects: 39
Study: 32933953

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment for insomnia (CBT‐I) for 8 weeks plus 4 bimonthly booster sessions
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sleep hygiene control group (SH)
Number of subjects: 130
Study: 35320285

Group type: EXPERIMENTAL
Intervention: Public health message reframing social distancing as recklessness rather than bravery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Public health message highlighting the need for everyone to take action to protect one another
Number of subjects: 0
Study: 35853017

Group type: COMPARATOR
Intervention: [68Ga]Ga-PSMA-11
Number of subjects: 100

Group type: COMPARATOR
Intervention: [18F]PSMA-1007
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Number of subjects: 100
Study: 33306114

Group type: EXPERIMENTAL
Intervention: Social norm email feedback program (2 emails with evidence-based information about nimodipine and individual prescription levels)
Number of subjects: 1811

Group type: COMPARATOR
Intervention: Control group (2 emails with general information about the risks of overprescription)
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Treatment group (opened emails)
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 1811
Study: 35863486

Group type: EXPERIMENTAL
Intervention: Tobramycin Inhalation Solution (300 mg/5 ml twice daily)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo (normal saline 5 ml twice daily)
Number of subjects: 339
Study: 32511154

Group type: EXPERIMENTAL
Intervention: Virtual reality distraction intervention
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 108
Study: 35275242

Group type: EXPERIMENTAL
Intervention: Percutaneous repair with intra-operative ultrasound (Group A)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Percutaneous repair without intra-operative ultrasound (Group B)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study: 32454239

Group type: EXPERIMENTAL
Intervention: Radiofrequency‐induced thermotherapy (RFiTT) combined with transilluminated powered phlebectomy (TIPP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: High ligation and stripping (HLS) combined with TIPP
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Radiofrequency‐induced thermotherapy (RFiTT) combined with TIPP
Number of subjects: 200
Study: 36228982

Group type: EXPERIMENTAL
Intervention: Web-based, rewards-based physical activity intervention for 6 months
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group receiving educational materials, activity monitor, web-based interface access, rewards based on physical activity levels at the end of the intervention
Number of subjects: 192